Dear all,
I would like to request your assistance in helping us
assessing the impact of the Prometheus and Myriad decisions of the US
Supreme Court on your IP and licensing strategy with respect to the medical
field , in particular diagnosis e.g. biomarkers.
The Questionaire for which we provide the following
link has been designed in order to collect the responses of the most
relevant TTOs worldwide.
Please complete it wherever you feel comfortable in
providing data and sharing your experience.
https://goo.gl/forms/3TyakNbrSUDAGcVe2
We hope to collect the response by the end of August.
All data will be anonymously processed and the
outcome of the questionnaire will be presented by Denise Hirsch, head of
The department “ Protection and Institutional partnerships “ of Inserm
Transfert , the private subsidiary of Inserm in charge of IP management and
Industrial Partnerships ,at the AIPPI congress of Milan that will take
place September 16-20 in the panel session entitled: “In(gene)ious but not
patentable? Patentable subject matter”.
http://www.aippi2016.it/wp/programme/
The outcome will also be shared with the responders in
advance of the Congress.
I thank you in advance for your kind assistance.
For any question, you may contact:
·
Sylvestre Chea: until August 19th
Sylvestre.chea@inserm-transfert.fr
Tel: +33 1 55 03 01 67
·
Pauline Solignac: from August 22nd
Pauline.solignac@inserm-transfert
Tel:+33 1 80 05 86 27
·
Denise Hirsch
Denise.hirsch@inserm-transfert.fr
Tel: +33 6 26 20 07 23